Mereo BioPharma MREO
NASDAQ MREO
$0.29 0.00 (-1.30%)
At close: Oct 22, 2026 · 4:00 PM EDT

Mereo BioPharma (MREO) Short term Debt (2022)

Updated

Mereo BioPharma (MREO) reported Short term Debt of $20.09 million for Q2 2022.

Analysis

Mereo BioPharma (MREO) Short term Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Mereo BioPharma 46.19 Mn -103.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 19.35 Mn
API Access

Mereo BioPharma Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=MREO&period=max&api_key=YOUR_API_KEY